deltatrials
Recruiting PHASE2 INTERVENTIONAL 2-arm NCT05052853

Early Intervention of Prodromal Schizophrenia Using an NMDA Enhancer

Sponsor: China Medical University Hospital

Conditions Prodromal Schizophrenia
Interventions NMDAE Placebo Cap
Updated 5 times since 2021 Last updated: Feb 7, 2023 Started: Nov 1, 2021 Primary completion: Oct 31, 2026 Completion: Dec 31, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Prodromal Schizophrenia, this trial is actively recruiting participants. The trial is conducted by China Medical University Hospital and has accumulated 5 data snapshots since 2021. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.

Status Flow

~Oct 2021 – ~Dec 2021 · 2 months · monthly snapshot~Dec 2021 – ~Mar 2023 · 15 months · monthly snapshotRecruiting~Mar 2023 – ~Jul 2024 · 16 months · monthly snapshotRecruiting~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 23 months · monthly snapshotRecruiting

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Recruiting PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE2

  3. Mar 2023 — Jul 2024 [monthly]

    Recruiting PHASE2

  4. Dec 2021 — Mar 2023 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  5. Oct 2021 — Dec 2021 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • China Medical University Hospital
Data source: China Medical University Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations